Document is current
Any future updates will be listed below
-
Authors
Yoshida, Yusuke
Hammer, Hilde Berner
Sexton, Joseph
Nordberg, Lena
Aga, Anna-Birgitte
Terslev, Lene
Lillegraven, Siri
Haarvardsholm, Espen A.
-
Funding
Funding for this research was provided by:
Japan Society for the Promotion of Science (24K18642)
Tsuchiya Memorial Medical Foundation
The Research Council of Norway (90825)
Horizon 2020 (779282)
- License Information
-
More Information
Article History
Received: 27 July 2025
Accepted: 29 September 2025
First Online: 30 October 2025
Declarations
:
: The ARCTIC trial and ULTRABIT study were approved by the Regional Committee for Medical and Health Research Ethics, South-East Norway (reference number: 2010/744 and 2009/1254, respectively), and all patients gave written consent according to the Declaration of Helsinki.
: Not applicable.
: YY received honoraria for the speakers bureau from Eisai, Asahi Kasei, Daiichi-Sankyo, AstraZeneca, Boehringer Ingelheim, AbbVie, and Astellas. HBH received speaking fees from AbbVie, UCB, and Novartis. ABA received honoraria from AbbVie, Lilly, Novartis, and Pfizer. LT has received speaker fees from UCB, Novartis, Janssen, and GE. EAH received honoraria from AbbVie, Eli Lilly, Novartis, and Pfizer. The other authors declared that they have no competing interests.
